5 Best Drug Stocks To Buy Now

2. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Number of Hedge Fund Holders: 38

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapeutics based on ribonucleic acid interference. 

On May 2, H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $430 from $400 and maintained a Buy rating on the shares. The analyst said the post-earnings selloff in the shares has created a “compelling” entry point ahead of APOLLO-B results. He also believes that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s hepatitis B virus program is best-in-class.

According to Insider Monkey’s Q1 data, 38 hedge funds were bullish on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), with collective stakes exceeding $1 billion. Kurt Von Emster’s VenBio Select Advisor is the leading shareholder of the company, with 1.30 million shares worth $212.2 million.